Myron Chu
Overview
Explore the profile of Myron Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peeva E, Guttman-Yassky E, Yamaguchi Y, Berman B, Oemar B, Ramakrishna J, et al.
Drug Discov Today
. 2025 Feb;
30(3):104317.
PMID: 39986647
Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and...
2.
Fiorentino D, Mangold A, Werth V, Christopher-Stine L, Femia A, Chu M, et al.
Lancet
. 2025 Jan;
405(10473):137-146.
PMID: 39798982
Background: Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess...
3.
Cohen S, Beebe J, Chindalore V, Guan S, Hassan-Zahraee M, Saxena M, et al.
Arthritis Res Ther
. 2024 Jun;
26(1):117.
PMID: 38845046
Background: The objective of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF‑06835375, a potent selective afucosyl immunoglobulin G1 antibody targeting C-X-C chemokine receptor type 5...
4.
Zheng J, Gu J, Su Y, Li Y, Li X, Xiong C, et al.
Mod Rheumatol
. 2022 Oct;
33(4):751-757.
PMID: 36208293
Objectives: To assess belimumab efficacy in patients from North East Asia (NEA) with systemic lupus erythematosus (SLE) in baseline demographic/disease characteristic subgroups. Methods: This analysis of patient subgroups from BLISS-NEA...
5.
Zhang F, Zheng J, Li Y, Wang G, Wang M, Su Y, et al.
RMD Open
. 2022 Apr;
8(1).
PMID: 35428697
Objectives: To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in China. Methods: In this phase 3, open-label extension period, eligible completers of...
6.
Bae S, Bass D, Chu M, Curtis P, Dimelow R, Harvey L, et al.
Arthritis Res Ther
. 2022 Feb;
24(1):46.
PMID: 35172878
Background: Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk...
7.
Tanaka Y, Bae S, Bass D, Curtis P, Chu M, DeRose K, et al.
RMD Open
. 2021 Jul;
7(2).
PMID: 34215703
Objectives: To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) from Japan and South Korea. Methods: In this phase III, open-label continuation study...
8.
Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D
Mod Rheumatol
. 2019 Jun;
30(2):313-320.
PMID: 31199180
To assess the effects of belimumab on disease activity across multiple organ domains in Japanese patients from the Phase 3 randomized, double-blind, North-East Asia study, BEL113750 (NCT01345253). Patients, aged ≥18...
9.
Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, et al.
Mod Rheumatol
. 2018 May;
29(3):452-460.
PMID: 29792370
Objectives: To assess the efficacy and safety of intravenous (IV) belimumab plus standard systemic lupus erythematosus (SLE) therapy standard of care (SoC) in Japanese patients with SLE. Methods: A Phase...
10.
Zhang F, Bae S, Bass D, Chu M, Egginton S, Gordon D, et al.
Ann Rheum Dis
. 2018 Jan;
77(3):355-363.
PMID: 29295825
Background: Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Methods: This phase III, multicentre, randomised,...